Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

64.49
+1.522.41%
Volume:553.24K
Turnover:36.11M
Market Cap:7.94B
PE:-9.86
High:67.11
Open:63.80
Low:63.80
Close:62.97
52wk High:70.98
52wk Low:29.31
Shares:123.16M
Float Shares:119.09M
Volume Ratio:0.79
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5400
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-27.08%
PB:-12.04
PE(LYR):-9.86

Loading ...

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

GlobeNewswire
·
Jan 27

Cytokinetics Announces Myqorzo™ (Aficamten) NOW Available in the U.S. for the Treatment of Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

THOMSON REUTERS
·
Jan 27

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

GlobeNewswire
·
Jan 27

Do Cytokinetics’ (CYTK) New-Hire Equity Grants Reveal a Deeper Shift in Its Talent Strategy?

Simply Wall St.
·
Jan 23

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Jan 23

Cytokinetics Price Target Maintained With a $95.00/Share by RBC Capital

Dow Jones
·
Jan 21

B. Riley Raises Price Target on Cytokinetics to $108 From $90, Keeps Buy Rating

MT Newswires Live
·
Jan 21

Cytokinetics price target raised to $108 from $90 at B. Riley

TIPRANKS
·
Jan 21

BRIEF-Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Jan 21

Cytokinetics Grants Stock Options and RSUs to New Employees

Reuters
·
Jan 21

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 21

Cytokinetics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

Leerink Partners Keeps Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Jan 14

Cytokinetics Inc : Jefferies Raises Target Price to $90 From $80

THOMSON REUTERS
·
Jan 09

Cytokinetics price target raised to $90 from $71 at Morgan Stanley

TIPRANKS
·
Jan 08

Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares

Reuters
·
Jan 03

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

Cytokinetics EVP Chief Commercial Officer Andrew Callos Reports Sale of Common Shares

Reuters
·
Dec 31, 2025

Director Wendell Wierenga Reports Disposal of Cytokinetics Incorporated Common Shares

Reuters
·
Dec 24, 2025